Day: February 16, 2026

The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 25,327 960.00 24,313,8059 February 2026 12,122 975.31 11,822,70910 February 2026 12,220 974.17 11,904,41011 February 2026 12,643 969.73 12,260,32912...

Aspo Plc Stock exchange release 16 February 2026 at 9.15 EET Share rewards from Aspo’s short-term remuneration plan The Board of Directors of Aspo has resolved that 50% of the remuneration earned by the CEO, members of the Group Executive Committee and other key employees of the company under the short-term remuneration plan 2026 will be paid in shares of Aspo Plc. The target group in the plan covers about 20 key people. The part payable in shares is estimated to be a maximum total of 160,000 shares (gross) calculated at the share price level prior to the resolution of the Board of Directors and provided that the targets set for the criteria are fully met. The share rewards payable based on the plan, subject to achievement of the performance measures, will be delivered to the participants in spring 2027. Aspo PlcBoard of Directors Distribution:Nasdaq...

Schindellegi, Switzerland – 16 February 2026 Trifork Group AGCompany announcement no. 9/2026 Weekly report on share buyback On 22 December 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 23 December 2025 up to and including no later than 26 February 2026. For details, please see company announcement no. 58 of 22 December 2025. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 14.92 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 219,735 treasury shares, corresponding to 1.1% of the share capital. Under the program, the following transactions...

16 FEBRUARY 2026 NORTHERN 3 VCT PLC NON-EXECUTIVE DIRECTOR APPOINTMENT AND DIRECTORATE CHANGE Northern 3 VCT PLC (“the Company”) is pleased to announce that it has appointed James (Jamie) Younger to the board as a non-executive director and as a member of the Company’s audit, nomination and management engagement committees with effect from 13 February 2026. It is also announced that Chris Fleetwood will retire as a non-executive director of the Company at the Company’s AGM later this year, on which date Jamie Younger will take over the role of Chair of the Company’s Audit & Risk Committee. Jamie is an ICAS qualified audit and business advisory partner in Saffery LLP, where he has served for 12 years in senior leadership roles and acts as client partner for a number of organisations. His audit experience includes listed investment...

Press ReleaseNicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470U.S. NDA submission on track for summer 2026 Nicox to receive milestone payment from Kowa upon submission of the NDA NDA submission based on Phase 3 clinical data showing NCX 470 lowered intraocular pressure by up to 10mmHg in patients with open-angle glaucoma or ocular hypertensionFebruary 16, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that it has received positive written feedback from its NCX 470 pre-NDA (New Drug Application) meeting with the U.S. Food and Drug Administration (FDA). The minutes confirm that the current data package and the proposed content and format of the proposed NDA application is generally...

MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years Up to 30% of people with membranous nephropathy progress to kidney failure over 10 years despite current treatment approaches; achieving complete remission can help delay or prevent this1,2 Gazyva/Gazyvaro could become the first approved treatment for primary membranous nephropathy, having already achieved positive results in lupus nephritis, systemic lupus erythematosus and idiopathic nephrotic syndrome Gazyva/Gazyvaro is a glycoengineered, anti-CD20 monoclonal antibody designed to achieve deep tissue B cell depletionBasel, 16 February 2026 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the phase III MAJESTY study in adults with primary membranous nephropathy met its primary endpoint,...

EfTEN United Property Fund earned a net profit of 223 thousand euros in January (the same period last year: 408 thousand euros). Decrease in profit was primarily related to the investment in EfTEN Real Estate Fund AS shares, which share price at Tallinn Stock Exchange increase by 2,9% in January 2026 as compared to 6,1% in January 2025. The net asset value (NAV) of the fund unit was 12,85 euros at the end of January, increasing by 0,8% per month. In Invego Uus-Järveküla OÜ, a development company in which the fund has an 80% stake, clients reserved a part of a terraced house in January, and in February, the handover of the terraced houses in the final stage of the development to clients began (signing property rights agreements). As of the end of the month, a total of 10 parts of a terraced house under construction had not yet been reserved...